Gain Therapeutics (GANX) Price & Analysis

Compare

280 Followers

GANX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.89 - $3.19

Previous CloseN/A

Volume74.47K

Average Volume (3M)276.83K

Market Cap

$50.47M

Enterprise Value$46.33M

Total Cash (Recent Filing)$9.07M

Total Debt (Recent Filing)$179.26K

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Nov 07, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding34,571,820

10 Day Avg. Volume249,751

30 Day Avg. Volume276,834

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.92

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.11K

Enterprise Value/Ebitda-2.28

Forecast

1Y Price Target

$8.17

Price Target Upside459.59% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Biomarker DataBiomarker data for Gain Therapeutics, Inc. is expected to be available ahead of schedule.

Clinical TrialsThe completion of enrollment for Phase 1b in Parkinson's is a significant milestone for Gain Therapeutics, Inc.

Financial PositionGain Therapeutics reported financial results with sufficient cash to fund operations into late 2025.

Bears Say

Clinical Trial RisksRisks for Gain Therapeutics include delays in advancing preclinical candidates, unexpected safety issues, and negative trial results.

Market RisksRisks include, but are not limited to: slower-than-expected market uptake.

Regulatory RisksRisks include, but are not limited to: failure to obtain regulatory approvals.

Gain Therapeutics News

Gain Therapeutics price target lowered to $6 from $7 at Roth Capital

Roth Capital lowered the firm’s price target on Gain Therapeutics (GANX) to $6 from $7 and keeps a...

11h ago

GANX

Gain Therapeutics reports Q2 EPS (19c), consensus (17c)

“Reaching target enrollment in the Phase 1b study of GT-02287 during 2Q 2025 was an exciting achievement for...

1d ago

GANX

Gain Therapeutics 7M share Spot Secondary priced at $1.55

Newbridge Securities acted as sole book running manager for the offering. Published first on TheFly – the ultimate...

28d ago

GANX

Gain Therapeutics prices 4.50M offering at $1.55 per share

Gain Therapeutics (GANX) announced the pricing of a public offering of 4.50M shares at $1.55 per share. Newbridge...

28d ago

GANX

Gain Therapeutics announces common stock, warrants offering

Gain Therapeutics (GANX) announced that it is proposing to offer and sell, subject to market conditions, shares of...

29d ago

GANX

Gain Therapeutics Announces $7 Million Public Offering

Gain Therapeutics ( ($GANX) ) has issued an update. On July 16, 2025, Gain Therapeutics, Inc. entered into...

27d ago

GANX

Buy Rating for Gain Therapeutics Driven by Accelerated Clinical Progress and Valuation Model

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on GANX stock, giving a Buy rating yesterday....

1M ago

GANX

Promising Developments and Strategic Advancements Propel Gain Therapeutics to ‘Buy’ Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Gain Therapeutics, retaining the price target of...

1M ago

GANX

Positive Outlook for Gain Therapeutics Amid Promising Biomarker Developments and Clinical Trial Progress

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Gain Therapeutics (GANX –...

1M ago

GANX

Gain Therapeutics Advances Phase 1b Parkinson’s Study

An announcement from Gain Therapeutics ( ($GANX) ) is now available. On June 30, 2025, Gain Therapeutics announced...

1M ago

GANX

Gain Therapeutics Doubles Authorized Common Stock Shares

Gain Therapeutics ( ($GANX) ) has shared an update. On June 24, 2025, Gain Therapeutics, Inc. held its...

2M ago

GANX

Gain Therapeutics files $100M mixed securities shelf

17:02 EDT Gain Therapeutics (GANX) files $100M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

GANX

Buy Rating for Gain Therapeutics: Promising Phase 1b Trial and Strong Financial Position Support Positive Outlook

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Gain Therapeutics (GANX – Research Report), retaining...

3M ago

GANX

Buy Rating for Gain Therapeutics Driven by Promising Parkinson’s Program and Strong Financial Position

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Gain Therapeutics (GANX – Research Report)....

3M ago

GANX

GANX FAQ

What was Gain Therapeutics’s price range in the past 12 months?

Gain Therapeutics lowest stock price was $0.89 and its highest was $3.19 in the past 12 months.

What is Gain Therapeutics’s market cap?

Gain Therapeutics’s market cap is $50.47M.

When is Gain Therapeutics’s upcoming earnings report date?

Gain Therapeutics’s upcoming earnings report date is Nov 07, 2025 which is in 86 days.

How were Gain Therapeutics’s earnings last quarter?

Gain Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.023.

Is Gain Therapeutics overvalued?

According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gain Therapeutics pay dividends?

Gain Therapeutics does not currently pay dividends.

What is Gain Therapeutics’s EPS estimate?

Gain Therapeutics’s EPS estimate is -0.14.

How many shares outstanding does Gain Therapeutics have?

Gain Therapeutics has 34,571,820 shares outstanding.

What happened to Gain Therapeutics’s price movement after its last earnings report?

Gain Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 4.795%.

Which hedge fund is a major shareholder of Gain Therapeutics?

Currently, no hedge funds are holding shares in GANX

Gain Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-290.21%

Trailing 12-Months

Asset Growth

-20.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Gain Therapeutics (GANX) Earnings & Revenues

Historic Earnings Reports

GANX Stock 12 Month Forecast

Average Price Target

$8.17

▲(459.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,2.252307692307692,3.0646153846153847,3.876923076923077,4.68923076923077,5.501538461538463,6.313846153846153,7.126153846153846,7.938461538461539,8.750769230769231,9.563076923076924,10.375384615384617,11.187692307692307,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.9576923076923076,2.4753846153846153,2.9930769230769227,3.5107692307692306,4.0284615384615385,4.546153846153846,5.063846153846153,5.581538461538461,6.099230769230768,6.616923076923076,7.134615384615385,7.6523076923076925,{"y":8.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.7138461538461538,1.9876923076923076,2.2615384615384615,2.5353846153846153,2.809230769230769,3.083076923076923,3.356923076923077,3.6307692307692307,3.9046153846153846,4.178461538461539,4.452307692307692,4.726153846153846,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.12,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >